489 related articles for article (PubMed ID: 28741090)
1. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
2. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
[TBL] [Abstract][Full Text] [Related]
4. An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
Li HJ; Bai WJ; Dai YT; Xu WP; Wang CN; Li HZ
Asian J Androl; 2016; 18(5):773-9. PubMed ID: 26459780
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
6. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
8. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
García-Perdomo HA; Echeverría-García F; Tobías A
Urol Int; 2017; 98(2):198-204. PubMed ID: 27509143
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
Wang Y; Bao Y; Liu J; Duan L; Cui Y
Low Urin Tract Symptoms; 2018 Jan; 10(1):84-92. PubMed ID: 29341503
[TBL] [Abstract][Full Text] [Related]
11. Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction.
von Büren M; Rodler S; Wiesenhütter I; Schröder F; Buchner A; Stief C; Gratzke C; Wülfing C; von Büren J
Eur Urol Focus; 2022 May; 8(3):794-802. PubMed ID: 34006491
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.
Mykoniatis I; Pyrgidis N; Sokolakis I; Ouranidis A; Sountoulides P; Haidich AB; van Renterghem K; Hatzichristodoulou G; Hatzichristou D
JAMA Netw Open; 2021 Feb; 4(2):e2036337. PubMed ID: 33599772
[TBL] [Abstract][Full Text] [Related]
13. The effect of statins on erectile dysfunction: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
J Sex Med; 2014 Jun; 11(6):1367-75. PubMed ID: 24628781
[TBL] [Abstract][Full Text] [Related]
14. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction.
Rosen R; Broderick G; Shabsigh R; Swindle R; Lockhart D; Cameron A
J Sex Med; 2005 Jul; 2(4):461-8. PubMed ID: 16422840
[TBL] [Abstract][Full Text] [Related]
17. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
19. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
